Jelena Grahovac

Dr. Jelena Grahovac

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JIJoao Incio
Joao Incio
HLHao Liu
Hao Liu
PSPriya Suboj
Priya Suboj
SCShan M. Chin
Shan M. Chin
ICIvy X. Chen
Ivy X. Chen
RJRakesh K. Jain
Rakesh K. Jain
It remains unclear how obesity worsens treatment outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes inflammation and fibrosis. We found in mouse models of PDAC that obesity also promotes desmoplasia associated with accelerated tumor growth and impaired delivery/efficacy of chemotherapeutics through reduced perfusion. Genetic and pharmacologic inhibition of angiotensin-II type-1 receptor reverses obesity-augmented desmoplasia and tumor growth and improves response to chemotherapy. Augmented activation of pancreatic stellate cells (PSC) in obesity is induced by tumor-associated neutrophils (TAN) recruited by adipocyte-secreted IL1β. PSCs further secrete IL1β, and inactivation of PSCs reduces IL1β expression and TAN recruitment. Furthermore, depletion of TANs, IL1β inhibition, or inactivation of PSCs prevents obesity-accelerated tumor growth. In patients with pancreatic cancer, we confirmed that obesity is associated with increased desmoplasia and reduced response to chemotherapy. We conclude that cross-talk between adipocytes, TANs, and PSCs exacerbates desmoplasia and promotes tumor progression in obesity. Significance: Considering the current obesity pandemic, unraveling the mechanisms underlying obesity-induced cancer progression is an urgent need. We found that the aggravation of desmoplasia is a key mechanism of obesity-promoted PDAC progression. Importantly, we discovered that clinically available antifibrotic/inflammatory agents can improve the treatment response of PDAC in obese hosts. Cancer Discov; 6(8); 852–69. ©2016 AACR. See related commentary by Bronte and Tortora, p. 821. This article is highlighted in the In This Issue feature, p. 803

1 May 2013 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
Alan WellsAlan Wells
Alan Wells
Jelena GrahovacJelena Grahovac
Jelena Grahovac
SWSarah Wheeler
Sarah Wheeler
Bo MaBo Ma
Bo Ma
DLDouglas Lauffenburger
Douglas Lauffenburger
Advances in diagnosis and treatment have rendered most solid tumors largely curable if they are diagnosed and treated before dissemination. However, once they spread beyond the initial primary location, these cancers are usually highly morbid, if not fatal. Thus, current efforts focus on both limiting initial dissemination and preventing secondary spread. There are two modes of tumor dissemination - invasion and metastasis - each leading to unique therapeutic challenges and likely to be driven by distinct mechanisms. However, these two forms of dissemination utilize some common strategies to accomplish movement from the primary tumor, establishment in an ectopic site, and survival therein. The adaptive behaviors of motile cancer cells provide an opening for therapeutic approaches if we understand the molecular, cellular, and tissue biology that underlie them. Herein, we review the signaling cascades and organ reactions that lead to dissemination, as these are non-genetic in nature, focusing on cell migration as the key to tumor progression. In this context, the cellular phenotype will also be discussed because the modes of migration are dictated by quantitative and physical aspects of the cell motility machinery.

1 January 2011 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Closed access
Alan WellsAlan Wells
Alan Wells
YCYvonne L Chao
Yvonne L Chao
Jelena GrahovacJelena Grahovac
Jelena Grahovac
QWQian Wu
Qian Wu
DLDouglas A Lauffenburger
Douglas A Lauffenburger
The most ominous stage of cancer progression is metastasis, or the dissemination of carcinoma cells from the primary site into distant organs. Metastases are often resistant to current extirpative therapies and even the newest biological agents cure only a small subset of patients. Therefore a greater understanding of tumor biology that integrates properties intrinsic to carcinomas with tissue environmental modulators of behavior is needed. In no aspect of tumor progression is this more evident than the acquisition of cell motility that is critical for both escape from the primary tumor and colonization. In this overview, we discuss how this behavior is modified by carcinoma cell phenotypic plasticity that is evidenced by reversible switching between epithelial and mesenchymal phenotypes. The presence or absence of intercellular adhesions mediate these switches and dictate the receptivity towards signals from the extracellular milieu. These signals, which include soluble growth factors, cytokines, and extracellular matrix embedded with matrikines and matricryptines will be discussed in depth. Finally, we will describe a new mode of discerning the balance between epithelioid and mesenchymal movement.

1 January 2014 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
Jelena GrahovacJelena Grahovac
Jelena Grahovac
Alan WellsAlan Wells
Alan Wells
Cancer invasion is a complex process requiring, among other events, extensive remodeling of the extracellular matrix including deposition of pro-migratory and pro-proliferative moieties. In recent years, it has been described that while invading through matrices cancer cells can change shape and adapt their migration strategies depending on the microenvironmental context. Although intracellular signaling pathways governing the mesenchymal to amoeboid migration shift and vice versa have been mostly elucidated, the extracellular signals promoting these shifts are largely unknown. In this review, we summarize findings that point to matrikines that bind specifically to the EGF receptor as matricellular molecules that enable cancer cell migrational plasticity and promote invasion.

28 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JDJulien Daubriac
Julien Daubriac
SHShiwei Han
Shiwei Han
Jelena GrahovacJelena Grahovac
Jelena Grahovac
ESEve Smith
Eve Smith
AHAbdel Hosein
Abdel Hosein
YBYves Boucher
Yves Boucher
The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1 The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1

1 June 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
PSPhilipp Schwabl
Philipp Schwabl
BPBerit A. Payer
Berit A. Payer
Jelena GrahovacJelena Grahovac
Jelena Grahovac
SKSabine Klein
Sabine Klein
THThomas Horvatits
Thomas Horvatits
MPMarkus Peck-Radosavljevic
Markus Peck-Radosavljevic